WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314264

CAS#: 38260-01-4

Description: Trientine, also known as Triethylenetetramine, abbreviated TETA and trien, is a chelating agent, and is used to bind up and remove copper in the body to treat Wilson's disease, particularly in those who are intolerant to penicillamine. Some recommend trientine as first-line treatment, but experience with penicillamine is more extensive. Trientine can also be used as stabilizer for epoxy resins, as ampholyte for isoelectric focusing and as chelating agent for copper in hepatolenticular degeneration.

Chemical Structure

CAS# 38260-01-4

Theoretical Analysis

MedKoo Cat#: 314264
Name: Trientine-2HCl
CAS#: 38260-01-4
Chemical Formula: C6H18N4
Exact Mass: 146.15315
Molecular Weight: 146.23
Elemental Analysis: C, 32.88; H, 9.20; Cl, 32.35; N, 25.56

Price and Availability

Size Price Availability Quantity
Bulk inquiry

Synonym: TETA; Trien; Triethylenetetramine; Triethylene tetramine; Trientine; Trientine HCl; Trientine dihydrochloride; brand name: Sypine.

IUPAC/Chemical Name: N1,N1'-(ethane-1,2-diyl)bis(ethane-1,2-diamine) dihydrochloride.


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 146.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Ala A, Aliu E, Schilsky ML. Prospective Pilot Study of a Single Daily Dosage of Trientine for the Treatment of Wilson Disease. Dig Dis Sci. 2015 Jan 21. [Epub ahead of print] PubMed PMID: 25605552.

2: Chandok N, Roberts EA. The trientine crisis in Canada: a call to advocacy. Can J Gastroenterol Hepatol. 2014 Apr;28(4):184. PubMed PMID: 24729990; PubMed Central PMCID: PMC4071922.

3: Fu S, Hou MM, Wheler J, Hong D, Naing A, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Falchook G, Kuo MT, Kurzrock R. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs. 2014 Jun;32(3):465-72. doi: 10.1007/s10637-013-0051-8. Epub 2013 Dec 5. PubMed PMID: 24306314.

4: Rezaei A, Heidarian E. Co-administration of trientine and flaxseed oil on oxidative stress, serum lipids and heart structure in diabetic rats. Indian J Exp Biol. 2013 Aug;51(8):646-52. PubMed PMID: 24228388.

5: Říha M, Karlíčková J, Filipský T, Macáková K, Hrdina R, Mladěnka P. Novel method for rapid copper chelation assessment confirmed low affinity of D-penicillamine for copper in comparison with trientine and 8-hydroxyquinolines. J Inorg Biochem. 2013 Jun;123:80-7. doi: 10.1016/j.jinorgbio.2013.02.011. Epub 2013 Mar 19. PubMed PMID: 23563391.

6: Wang CY, Xie JW, Xu Y, Wang T, Cai JH, Wang X, Zhao BL, An L, Wang ZY. Trientine reduces BACE1 activity and mitigates amyloidosis via the AGE/RAGE/NF-κB pathway in a transgenic mouse model of Alzheimer's disease. Antioxid Redox Signal. 2013 Dec 10;19(17):2024-39. doi: 10.1089/ars.2012.5158. Epub 2013 May 3. PubMed PMID: 23541064; PubMed Central PMCID: PMC3869419.

7: Kim B, Chung SJ, Shin HW. Trientine-induced neurological deterioration in a patient with Wilson's disease. J Clin Neurosci. 2013 Apr;20(4):606-8. doi: 10.1016/j.jocn.2012.02.041. Epub 2012 Dec 27. PubMed PMID: 23274038.

8: Moya-Olano L, Milne HM, Robinson JM, Hill JV, Frampton CM, Abbott HF, Turner R, Kettle AJ, Endre ZH. Trientine and renin-angiotensin system blockade ameliorate progression of glomerular morphology in hypertensive experimental diabetic nephropathy. Pathol Int. 2011 Nov;61(11):652-61. doi: 10.1111/j.1440-1827.2011.02721.x. PubMed PMID: 22029676.

9: Park HK, Lee JH, Lee MC, Chung SJ. Teaching NeuroImages: MRI reversal in Wilson disease with trientine treatment. Neurology. 2010 Apr 27;74(17):e72. doi: 10.1212/WNL.0b013e3181dad5cc. PubMed PMID: 20421574.

10: KADOWAKI S, ENDOH D, OKUI T, HAYASHI M. Trientine, a copper-chelating agent, induced apoptosis in murine fibrosarcoma cells by activation of the p38 MAPK pathway. J Vet Med Sci. 2009 Nov;71(11):1541-4. PubMed PMID: 19959910.

11: Brewer GJ, Askari F, Dick RB, Sitterly J, Fink JK, Carlson M, Kluin KJ, Lorincz MT. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Transl Res. 2009 Aug;154(2):70-7. doi: 10.1016/j.trsl.2009.05.002. Epub 2009 Jun 6. PubMed PMID: 19595438.

12: Baynes JW, Murray DB. The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat. Exp Diabetes Res. 2009;2009:696378. doi: 10.1155/2009/696378. Epub 2009 Apr 15. PubMed PMID: 19390595; PubMed Central PMCID: PMC2669293.

13: Taylor RM, Chen Y, Dhawan A; EuroWilson Consortium. Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King's College Hospital and review of the literature. Eur J Pediatr. 2009 Sep;168(9):1061-8. doi: 10.1007/s00431-008-0886-8. Epub 2008 Dec 9. Review. PubMed PMID: 19066958.

14: Park HK, Kim SM, Choi CG, Lee MC, Chung SJ. Effect of trientine on manganese intoxication in a patient with acquired hepatocerebral degeneration. Mov Disord. 2008 Apr 15;23(5):768-70. doi: 10.1002/mds.21957. PubMed PMID: 18307260.

15: Fox AN, Schilsky M. Once daily trientine for maintenance therapy of Wilson disease. Am J Gastroenterol. 2008 Feb;103(2):494-5. doi: 10.1111/j.1572-0241.2007.01646_15.x. PubMed PMID: 18289222.

16: Hayashi M, Hirai R, Ishihara Y, Horiguchi N, Endoh D, Okui T. Combined effects of treatment with trientine, a copper-chelating agent, and x-irradiation on tumor growth in transplantation model of a murine fibrosarcoma. J Vet Med Sci. 2007 Oct;69(10):1039-45. PubMed PMID: 17984591.

17: Arnon R, Calderon JF, Schilsky M, Emre S, Shneider BL. Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride (trientine) treatment. J Pediatr Gastroenterol Nutr. 2007 May;44(5):596-602. PubMed PMID: 17460493.

18: Hayashi M, Nishiya H, Chiba T, Endoh D, Kon Y, Okui T. Trientine, a copper-chelating agent, induced apoptosis in murine fibrosarcoma cells in vivo and in vitro. J Vet Med Sci. 2007 Feb;69(2):137-42. PubMed PMID: 17339757.

19: Ping CC, Hassan Y, Aziz NA, Ghazali R, Awaisu A. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease. J Clin Pharm Ther. 2007 Feb;32(1):101-7. PubMed PMID: 17286794.

20: Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol. 2006 Apr;63(4):521-7. PubMed PMID: 16606763.